About: Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.75 (-3.25%)
NYRASXNyrada Inc
Loading watchlist status…
Nyrada Inc share price
NYR price activity
Last Price
Change (24hr)
AUD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
NYR price performance
0.68%
5D
16.41%
1M
-33.48%
YTD
198%
1Y
NYR price fundamentals
N/A
Shares Issued
N/A
Earnings Per Share (EPS)
N/A
Dividends Per Share (DPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
AU-ASX rank
N/ASector Rank
N/ANYR Market Signals